Development, characterization and evaluation of protective efficacy of self amplifying mRNA vaccine candidates against the Severe acute respiratory syndrome coronavirus 2 (SARS CoV2)
- Funded by BIRAC
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Funder
BIRACPrincipal Investigator
Milan SurjitResearch Location
IndiaLead Research Institution
Translational Health Science and Technology Institute (THSTI)Research Priority Alignment
N/A
Research Category
Vaccines research, development and implementation
Research Subcategory
Clinical trial (unspecified trial phase)
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
Propose to evaluate the efficacy of self-amplifying mRNA SAM technology to develop a potent vaccine against the SARSCoV-2. Our approach involves production of vaccine antigen inside the host by delivering a self-amplifying mRNA that encodes the antigen of interest. S protein of SARS-CoV-2 is being used as the vaccine antigen.